Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/66343
Title: Discovery of novel rivastigmine-hydroxycinnamic acid hybrids as multi-targeted agents for Alzheimer's disease
Authors: Chen, ZW
Digiacomo, M
Tu, YL
Gu, Q
Wang, SN
Yang, XH
Chu, JQ
Chen, QH
Han, YF 
Chen, JK
Nesi, G
Sestito, S
Macchia, M
Rapposelli, S
Pi, RB
Keywords: Rivastigmine
Caffeic acid
Ferulic acid
Hybrid
Multifunctional agents
Alzheimer's disease
Issue Date: 2017
Publisher: Elsevier Masson
Source: European journal of medicinal chemistry, 5 Jan. 2017, v. 125, p. 784-792 How to cite?
Journal: European journal of medicinal chemistry 
Abstract: A series of rivastigmine-caffeic acid and rivastigmine-ferulic acid hybrids were designed, synthesized, and evaluated as multifunctional agents for Alzheimer's disease (AD) in vitro. The new compounds exerted antioxidant neuroprotective properties and good cholinesterases (ChE) inhibitory activities. Some of them also inhibited amyloid protein (A beta) aggregation. In particular, compound 5 emerged as promising drug candidates endowed with neuroprotective potential, ChE inhibitory, A beta self-aggregation inhibitory and copper chelation properties. These data suggest that compound 5 offers an attractive starting point for further lead optimization in the drug-discovery process against AD.
URI: http://hdl.handle.net/10397/66343
EISSN: 0223-5234
DOI: 10.1016/j.ejmech.2016.09.052
Appears in Collections:Journal/Magazine Article

Access
View full-text via PolyU eLinks SFX Query
Show full item record

SCOPUSTM   
Citations

3
Citations as of Aug 18, 2017

WEB OF SCIENCETM
Citations

4
Citations as of Aug 12, 2017

Page view(s)

10
Last Week
1
Last month
Checked on Aug 13, 2017

Google ScholarTM

Check

Altmetric



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.